The efficacy of agomelatine in previously-treated depressed patients

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 814-821

  Kasper, Siegfried ^a   Hajak, Göran ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Social Foundation Bamberg   (Germany)

Author keywords

Agomelatine; Depression; Efficacy; Meta analysis; Sertraline

Indexed keywords

AGOMELATINE; CITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; PAROXETINE; SERTRALINE; TIANEPTINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; XEROSTOMIA;

AGOMELATINE; DEPRESSION; EFFICACY; META-ANALYSIS; SERTRALINE;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, MELATONIN; RECURRENCE; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 84881661329     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.010     Document Type: Article

References (34)

1. Boivin D.B. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J. Psychiatry Neurosci. 2000, 35:446-458.
2. Brent D., Emslie G., Clarke G., Wagner K.D., Asarnow J.R., Keller M., Vitiello B., Ritz L., Iyengar S., Abebe K., Birmaher B., Ryan N., Kennard B., Hughes C., DeBar L., McCracken J., Strober M., Suddath R., Spirito A., Leonard H., Melhem N., Porta G., Onorato M., Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008, 299:901-913.
3. Bull S.A., Hu X.H., Hunkeler E.M., Lee J.Y., Ming E.E., Markson L.E., Fireman B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002, 288:1403-1409.
4. Cipriani A., Furukawa T.A., Geddes J.R., Malvini L., Signoretti A., McGuire H., Churchill R., Nakagawa A., Barbui C. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J. Clin. Psychiatry 2008, 69:1732-1742. MANGA Study Group.
5. De Bodinat C., Guardiola-Lemaitre B., Mocaër E., Renard P., Muñoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 2010, 9:628-642.
6. Germain A., Kupfer D.J. Circadian rhythm disturbances in depression. Hum. Psychopharmacol. 2008, 23:571-585.
7. Hasin D.S., Goodwin R.D., Stinson F.S., Grant B.F. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on alcoholism and related conditions. Arch. Gen. Psychiatry 2005, 62:1097-1106.
8. Hotopf M., Hardy R., Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br. J. Psychiatry 1997, 170:120-127.
9. Kasper S., Hajak G., Wulff K., Hoogendijk W.J., Montejo A.L., Smeraldi E., Rybakowski J.K., Quera-Salva M.A., Wirz-Justice A.M., Picarel-Blanchot F., Baylé F.J. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 2010, 71:109-120.
10. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry 2009, 10:117-126.
11. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 2006, 16:93-100.
12. Kennedy S.H., Rizvi S.J. Agomelatine in the treatment of major depressive disorder. CNS Drugs 2010, 24:479-499.
13. Kennedy S.H., Rizvi S., Fulton K., Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol. 2008, 28:329-333.
14. Kessler R.C., Birnbaum H., Bromet E., Hwang I., Sampson N., Shahly V. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol. Med. 2010, 40:225-237.
15. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double blind comparison with venlafaxine. J. Clin. Psychiatry 2007, 68:1723-1732.
16. Linden M., Gothe H., Dittmann R.W., Schaaf B. Early termination of antidepressant drug treatment. J. Clin. Pharmacol. 2000, 20:523-530.
17. LÔo H., Hale A., D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17:239-247.
18. McAllister-Williams R.H., Baldwin D.S., Haddad P.M., Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum. Psychopharmacol.: Clin. Exp. 2010, 25:95-102.
19. Montgomery S.A., Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol. 2007, 22:283-291.
20. Montgomery S.A., Kennedy S.H., Burrows G.D., Lejoyeux M., Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 2004, 19:271-280.
21. Morilak D.A., Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 2007, 7:193-218.
22. Olfson M., Marcus S., Tedeschi M. Continuity of antidepressant treatment for adults with depression in the United States. Am. J. Psychiatry 2006, 163:101-108.
23. Olié J.P., Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 2007, 10:661-673.
24. Papakostas G.I. Tolerability of modern antidepressants. J. Clin. Psychiatry 2008, 69:8-13.
25. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol. Psychiatry 2008, 63:699-704.
26. Patten S.B. Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry 2009, 9:19.
27. Quera-Salva M.A., Hajak G., Philip P., Montplaisir J., Keufer-Le Gall S., Laredo J., Guilleminault C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int. Clin. Psychopharmacol. 2011, 26:252-262.
28. Quera Salva M.A., Vanier B., Laredo J., Hartley S., Chapotot F., Moulin C., Lofaso F., Guilleminault C. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J. Neuropsychopharmacol. 2007, 10:691-696.
29. Ruhé H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 2006, 67:1836-1855.
30. Schosser A., Calati R., Serretti A., Massat I., Kocabas N.A., Papageorgiou K., Linotte S., Mendlewicz J., Souery D., Zohar J., Juven-Wetzler A., Montgomery S., Kasper S. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder-a European Multicenter Study. Eur. Neuropsychopharmacol. 2012, 22:259-266.
31. Souêtre E., Salvati E., Belugou J.L., Pringuey D., Candito M., Krebs B., Ardisson J.L., Darcourt G. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res. 1989, 28:263-278.
32. Warden D., Trivedi M.H., Wisniewski S.R., Davis L., Nierenberg A.A., Gaynes B.N., Zisook S., Hollon S.D., Balasubramani G.K., Howland R., Fava M., Stewart J.W., Rush A.J. Predictors of attrition during initial (citalopram) treatment for depression: a STAR**D report. Am. J. Psychiatry 2007, 164:1189-1197.
33. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe. Eur. Neuropsychopharmacol. 2011, 21:655-679.
34. Yous S., Andrieux J., Howell H.E., Morgan P.J., Renard P., Pfeiffer B., Lesieur D., Guardiola-Lemaitre B. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem. 1992, 35:1484-1486.